Navigation Links
AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
Date:2/21/2008

WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- AstraZeneca believes this lawsuit is legally and factually unfounded and we intend to appeal to the Alabama Supreme Court, if the trial court does not reject the jury's verdict. The case was based on the misleading premise that the Alabama State Medicaid Agency did not understand the basics on how drug prices are established and reported.

We believe numerous errors occurred during the proceedings and that the verdict should not be upheld.

For example, the Court ruled that important information on the workings of the Alabama pharmacy system be withheld throughout the trial. The Court also permitted evidence of earlier, unrelated settlements and proceedings in clear violation of the rules of evidence. These and other reversible errors were compounded by negative public comments by the trial lawyers and state leaders prior to the jury selection process.

AstraZeneca has fully complied with the law, government guidelines and contracts that govern Medicaid pricing. We currently provide medicines to Medicaid programs at the lowest price that we offer to our best business clients, as federal law requires.

AstraZeneca and the State Medicaid program share a common goal of helping people access the medicines they need.

To help patients who have difficulty affording their medicines, we offer patient assistance programs side by side with our medicines. In the last two years alone, AstraZeneca helped more than 28,800 Alabama patients receive more than $25.5 million in savings through its prescription savings programs.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
2. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
6. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
7. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
10. Triage study challenges notions of emergency medical response to disaster
11. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... Building on the success of the inaugural RAADfest last year, ... latest developments in radical life extension. RAADfest combines cutting edge science presented for a ... personal development, making it the largest most comprehensive and inclusive super longevity event in ...
(Date:6/22/2017)... Boston, MA (PRWEB) , ... June 22, 2017 ... ... Kingdom-based social media network RegMedNet has produced a Spotlight ... has featured scholarly reviews and perspectives by leading experts on the unique regulatory ...
(Date:6/22/2017)... ... 22, 2017 , ... RURO, Inc., a leading LIMS, RFID, ... content-packed update to the Limfinity® framework. , LimitLIS® and other RURO solutions based ... of customers among labs and other businesses. Limfinity® 6.5 adds new features and ...
(Date:6/20/2017)... Fort Lauderdale, Florida (PRWEB) , ... June 20, 2017 , ... ... and commitment in men. While researching her latest book, Men Chase, Women Choose: The ... that showed that love has a physiological effect on men. ”The logical next step, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):